Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation
Diabetes Research and Clinical Practice, pp. e38-e41, 2010.
We investigated the impact of metabolic syndrome (MS) on the occurrence of in-stent restenosis (ISR) and long-term major adverse cardiac events (MACEs), including cardiovascular death, myocardial infarction, and target vessel revascularization (TVR) during a follow-up period of 36 months after percutaneous coronary intervention (PCI) with...More
Get fulltext within 24h
Full Text (Upload PDF)
PPT (Upload PPT)